Key terms

About IMVT

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.

Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest IMVT news

Mar 27 4:07pm ET Immunovant initiated with an Outperform at Oppenheimer Mar 21 1:15pm ET Buy Rating for Immunovant Amidst Strong Market Position and Promising Batoclimab Trials Mar 21 10:54am ET Roche’s mixed myasthenia gravis data sending these stocks in opposite directions Mar 21 10:54am ET Roche’s mixed myasthenia gravis data sending these stocks in opposite directions Mar 21 8:18am ET Tourmaline Bio might see weakness today after Roche MG data, says Truist Mar 21 8:12am ET Immunovant rallies after Chugai myasthenia gravis study failure Mar 13 5:25am ET Immunovant Inc.: A Strong Buy on IMVT-1402’s Market Potential and Upcoming Clinical Catalysts Mar 13 5:17am ET Immunovant initiated with a Buy at Goldman Sachs Mar 12 7:51am ET Immunovant awarded U.S. patent for IMVT-1402 Feb 20 5:22am ET Immunovant initiated with an Overweight at JPMorgan Feb 15 1:16am ET Buy Rating Affirmed on Immunovant’s Promising Pipeline and Strategic Clinical Advancements Feb 14 7:17pm ET Wolfe starts Immunovant at Outperform, says excited about catalyst path Feb 14 4:16pm ET Immunovant initiated with an Outperform at Wolfe Research Feb 13 6:20am ET Analysts Are Bullish on Top Healthcare Stocks: Immunovant (IMVT), 4D Molecular Therapeutics (FDMT) Feb 13 6:16am ET Buy Rating Affirmed: Immunovant’s Expansion and IMVT-1402’s Market Potential Feb 13 5:55am ET Buy Rating Justified: Immunovant’s Strategic Clinical Advancements and Lead Drug Candidate Promise Feb 13 5:03am ET Buy Rating Affirmed on Immunovant Amidst Strategic Growth and Pipeline Strength Feb 13 4:59am ET Immunovant (IMVT) Poised for Growth: A Buy Rating Backed by Strong Pipeline and Upcoming Catalysts Feb 13 1:00am ET Immunovant, Inc. Is Worried About This – Should You Be Worried Too? Feb 12 3:04pm ET Immunovant options imply 3.5% move in share price post-earnings Feb 12 12:47pm ET Immunovant remains attractive despite stock underperformance, says Wells Fargo Feb 12 7:02am ET Immunovant reports Q3 EPS (36c), consensus (43c) Feb 05 3:55pm ET Immunovant’s Buy Rating: Market Opportunities and Positive Trial Outcomes for Batoclimab Jan 02 12:13pm ET The biotech stocks to own in 2024, according to Piper Sandler

No recent news articles are available for IMVT

No recent press releases are available for IMVT

IMVT Financials

1-year income & revenue

Key terms

IMVT Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

IMVT Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms